Drug Topics
JANUARY 16, 2025
Researchers compared the safety and reactogenicity of simultaneous doses of recombinant zoster vaccine paired with 2 separate types of inactivated influenza vaccines.
STAT
JANUARY 16, 2025
SAN FRANCISCO — On the first day of the J.P Morgan Healthcare Conference, a small crowd of demonstrators gathered on a corner of Union Square just opposite of the conference’s main venue, the Westin St. Francis hotel. It was a varied crew — musicians, health care workers, teachers, and others. Steve Zeltzer, a labor journalist and organizer, spoke before the group and held a sign saying, “No more Deny, Delay, Depose,” alluding to words inscribed on the bu
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JANUARY 16, 2025
Known as The Nutrition Pharmacist, Sarah Gray, PharmD, GAICD, recently joined Drug Topics to discuss her dual profession within health care.
STAT
JANUARY 16, 2025
SAN FRANCISCO — One of the U.S. biotech industry’s preferred partners in China, Jiangsu Hengrui Pharmaceuticals, emphasized its global ambitions and plans for more dealmaking at a presentation at the J.P. Morgan Healthcare Conference Thursday. “In the last two decades, [Hengrui] has grown from a China-focused generics company to one of the largest innovative medicine companies in the world,” the company’s chief strategy officer, Frank Jiang, said at
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JANUARY 16, 2025
A conversation with Jennifer Bacci, PharmD, MPH, endowed associate professor of Innovative Pharmacy Practice at the University of Washington School of Pharmacy.
The Checkup by Singlecare
JANUARY 16, 2025
If Repatha were ever to leave the market, there are other, non-statin medications doctors can use. Some options include : Repatha (evolocumab) is a brand-name medication that is FDA approved to lower cholesterol and reduce the risk of heart attacks and strokes, by helping to restore blood flow to the heart in individuals with heart disease. Similar to statins, Repatha is a cholesterol-lowering prescription drug.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
DiversifyRx
JANUARY 16, 2025
Growing and retaining your non-PBM revenue is one of the keys to success in 2024 and beyond. Non-PBM revenue has become a cornerstone for independent pharmacies striving to maintain profitability and thrive in an industry dominated by Pharmacy Benefit Managers (PBMs). By diversifying income streams beyond PBM reimbursements, pharmacies can achieve greater financial stability and deliver enhanced value to their communities.
Fierce Healthcare
JANUARY 16, 2025
UnitedHealth Group reported $5.5 billion in profit for the fourth quarter of 2024, on par with its haul a year prior. | UnitedHealth Group reported $5.5 billion in profit for the fourth quarter of 2024, on par with its haul a year prior.
Pharmacy Times
JANUARY 16, 2025
This is mirikizumabs second FDA-approved indication in inflammatory bowel disease.
Fierce Healthcare
JANUARY 16, 2025
About 44 million people were covered under one of the Affordable Care Act's initiatives, from the insurance marketplaces to Medicaid expansion, according to a new report from KFF.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JANUARY 16, 2025
The combination yields promising results but was associated with high incidence of toxicity and infection.
Fierce Healthcare
JANUARY 16, 2025
The cancer mortality rate dropped by 34% from 1991 to 2022. This saved about 4.5 million lives. Still, incidence rates in women between ages 50 and 64 have surpassed men, and rates in women under 50 are 82% higher than in men.
Hospital Pharmacy Europe
JANUARY 16, 2025
A new global study from the International Pharmaceutical Federation (FIP)s Pediatric Formulations Focus Group is the first to report current and global paediatric oral extemporaneous compounding practices. Here, lead author and focus group chair Hala Fadda discusses the reasons for widespread off-label prescribing, the FIP studys rationale and main findings, compounding challenges and considerations for improving clinical practice.
Fierce Healthcare
JANUARY 16, 2025
Alignment Healthcare is the latest Medicare Advantage (MA) insurer to accuse the Centers for Medicare & Medicaid Services (CMS) of wrongly calculating the companys star rating scores. | Insurers, perhaps smelling blood in the water, continue to question elements and scoring of the CMS star ratings program in court.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The FDA Law Blog
JANUARY 16, 2025
Hyman, Phelps & McNamara PC, (HPM), which will mark its 45thAnniversary on March 17, 2025, is pleased to announce that it is increasing its directors, counsel, and associates as it starts the year. Kalie E. Richardson has been promoted to Director. Mark Tobolowsky has been promoted to Counsel; and Esther Petrikovsky is joining the firm as an Associate.
Fierce Healthcare
JANUARY 16, 2025
Medicare Advantage (MA) insurers Alignment Healthcare and Clover Health both reported increased membership growth ahead of the J.P. Morgan Healthcare Conference this week. | Only Alignment Healthcare and Clover Health represented insurers at the J.P Morgan Healthcare Conference this year. Here's what they had to say.
Pharmacy Times
JANUARY 16, 2025
Rite Aid survey highlights underutilized role of pharmacists in health care, with 62% of respondents viewing their pharmacists as a crucial part of their health and wellness care team.
Pharmaceutical Technology
JANUARY 16, 2025
Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult population.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JANUARY 16, 2025
AI start-up Bioptimus takes its funding above $76m as it prepares for the launch of a universal foundation model for pathology later this year.
Pharmaceutical Technology
JANUARY 16, 2025
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
pharmaphorum
JANUARY 16, 2025
Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth
Pharmaceutical Technology
JANUARY 16, 2025
At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling effect on clients.
Pharmacy Times
JANUARY 16, 2025
The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.
pharmaphorum
JANUARY 16, 2025
The FDA has banned the use of a red dye used in oral medicines, foods, and dietary supplements, more than 30 years after it was linked to cancer.
The Guardian - Pharmaceutical Industry
JANUARY 16, 2025
From aviation to retail, many industries are already looking to artificial intelligence to improve productivity Keir Starmer this week announced a 50-point plan that aims to give the UK world leader status in artificial intelligence and grow the economy by as much as 47bn a year over a decade. The multibillion-pound investment , which seeks to create a 20-fold increase in the amount of AI computing power under public control by 2030, has been framed as a gamechanger for businesses and public org
pharmaphorum
JANUARY 16, 2025
Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage
Outsourcing Pharma
JANUARY 16, 2025
Driving Innovation in Clinical Trials: Patient Perspectives and Multidimensional Assessments
pharmaphorum
JANUARY 16, 2025
Across every corner of the industry, from research and development to patient engagement, AI, and most recently generative AI (GenAI), is driving profound change.
Outsourcing Pharma
JANUARY 16, 2025
Explore WCG's cutting-edge AI and tech solutions, including ClinSphere Total Enrollment, transforming clinical trials at SCOPE 2025.
pharmaphorum
JANUARY 16, 2025
Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).
Outsourcing Pharma
JANUARY 16, 2025
Discover Medable's latest advancements in decentralized clinical trials, including AI-driven tools and enhanced eCOA solutions, at SCOPE 2025.
Fierce Healthcare
JANUARY 16, 2025
A new lawsuit from a drug manufacturer, this time by Teva Pharmaceuticals, is challenging CMS on the Inflation Reduction Act's drug price negotiation program.
Pharmacy Times
JANUARY 16, 2025
The current approved dose of axatilimab-csfr is 0.3 mg/kg up to a maximum dose of 35 mg and will be administered as an intravenous infusion over 30 minutes every 2 weeks.
Expert insights. Personalized for you.
469 
Let's personalize your content